公开(公告)号：WO2011146892A9

公开(公告)日：2012-03-08

申请号：PCT/US2011037440

申请日：2011-05-20

Applicant: SOUND PHARMACEUTICALS INC ,  PACIFIC NORTHWEST DIABETES RES INST ,  KIL JONATHAN ,  LYNCH ERIC D ,  ROBERTSON PAUL R

Inventor： KIL JONATHAN ,  LYNCH ERIC D ,  ROBERTSON PAUL R

IPC: A61K31/41 ,  A61K31/095 ,  A61P3/00 ,  A61P3/04 ,  A61P3/10

CPC classification number: A61K31/41 ,  A61K31/095 ,  A61K33/04 ,  A61K47/61 ,  C08L5/16

公开(公告)号：WO2011146892A2

公开(公告)日：2011-11-24

申请号：PCT/US2011/037440

申请日：2011-05-20

Applicant: SOUND PHARMACEUTICALS, INC. ,  PACIFIC NORTHWEST DIABETES RESEARCH INSTITUTE ,  KIL, Jonathan ,  LYNCH, Eric, D. ,  ROBERTSON, Paul, R.

Inventor： KIL, Jonathan ,  LYNCH, Eric, D. ,  ROBERTSON, Paul, R.

CPC classification number: A61K31/41 ,  A61K31/095 ,  A61K33/04 ,  A61K47/61 ,  C08L5/16

Abstract: Compositions and methods for the treatment and prevention of disorders associated with impaired insulin production or secretion including hyperglycemia and obesity are provided herein. Compositions and methods for promoting the production of insulin are also provided. The methods described herein include administering a therapeutically effective amount of an insulin-promoting composition including at least one seleno-organic compound.

Abstract translation: 本文提供了用于治疗和预防与胰岛素产生或分泌受损的疾病有关的组合物和方法，包括高血糖症和肥胖症。 还提供了促进胰岛素生成的组合物和方法。 本文描述的方法包括施用治疗有效量的包含至少一种硒 - 有机化合物的胰岛素促进组合物。

公开(公告)号：WO2006096759A3

公开(公告)日：2007-04-05

申请号：PCT/US2006008201

申请日：2006-03-08

Applicant: SOUND PHARMACEUTICALS INC ,  KIL JONATHAN ,  LYNCH ERIC DANIEL

Inventor： KIL JONATHAN ,  LYNCH ERIC DANIEL

IPC: A61K31/095 ,  A61K31/52

CPC classification number: A61K31/282 ,  A61K31/337 ,  A61K31/41 ,  A61K31/519 ,  A61K31/555

Abstract: In one aspect the present invention provides methods for treating cancer in a mammal, including the step of administering to a mammal suffering from a cancer an amount of ebselen that is sufficient to inhibit the growth of the cancer. In another aspect, the present invention provides methods for enhancing the chemotherapeutic effect of a platinum-containing chemotherapeutic agent administered to a mammal suffering from cancer.

Abstract translation: 一方面，本发明提供了用于治疗哺乳动物癌症的方法，其中包括向患有癌症的哺乳动物施用足以抑制癌症生长的量的依他硒的量的步骤。 另一方面，本发明提供了增加施用于患有癌症的哺乳动物的含铂化学治疗剂的化疗效果的方法。

公开(公告)号：WO0204605A3

公开(公告)日：2003-02-27

申请号：PCT/US0121793

申请日：2001-07-10

Applicant: SOUND PHARMACEUTICALS INC

Inventor： KIL JONATHAN ,  GU RENDU ,  GRIGEUR CORINNE ,  LOWENHEIM HUBERT

IPC: C12N15/09 ,  A61K31/282 ,  A61K31/519 ,  A61K31/711 ,  A61K33/14 ,  A61K33/24 ,  A61K38/00 ,  A61K38/17 ,  A61K45/00 ,  A61K45/06 ,  A61K48/00 ,  A61P27/16 ,  A61P43/00 ,  C12N5/0793 ,  C12N5/06

CPC classification number: A61K38/1709 ,  C12N5/062 ,  C12N2501/40 ,  C12N2501/60

Abstract: The present invention provides methods for stimulating the formation of inner ear cells, including inner ear sensory hair cells and inner ear support cells. The methods of the present invention damage and/or kill inner ear cells, and stimulate the formation of new, inner ear cells.

Abstract translation: 本发明提供刺激内耳细胞形成的方法，包括内耳感觉毛细胞和内耳支持细胞。 本发明的方法损伤和/或杀死内耳细胞，并刺激新的内耳细胞的形成。

公开(公告)号：WO2016033615A8

公开(公告)日：2016-06-30

申请号：PCT/US2015048178

申请日：2015-09-02

Applicant: SOUND PHARMACEUTICALS INC

Inventor： KIL JONATHAN ,  LYNCH ERIC D

IPC: A61B5/12 ,  A61K38/00

CPC classification number: A61B5/12 ,  A61B5/4848 ,  A61K31/145 ,  A61K31/198 ,  A61K31/41 ,  A61K31/7076 ,  A61K38/063 ,  A61K38/44 ,  C12Y111/01009 ,  A61K2300/00

Abstract: The invention relates to methods of identifying a composition useful for the prevention or treatment of noise-induced hearing loss. The method includes exposing a mammalian test subject to a candidate composition and a calibrated sound or noise challenge. Next, a temporary threshold shift (TTS) is monitored in the test subject over a period of time. The monitored TTS is compared with a TTS of a control subject exposed to a control composition. The presence or absence is determined by clinically relevant and statistically significant differences between the monitored TTS in the test subject and the TTS of the control subject, and the presence of a statistically significant difference identifies the candidate composition as useful for prevention or treatment of noise-induced hearing loss.

Abstract translation: 本发明涉及鉴定可用于预防或治疗噪声诱发的听力损失的组合物的方法。 该方法包括将哺乳动物测试对象暴露于候选组合物以及校准的声音或噪音挑战。 接下来，在一段时间内在受测者中监测临时阈值转换（TTS）。 将所监测的TTS与暴露于对照组合物的对照受试者的TTS进行比较。 存在或不存在由测试受试者中监测到的TTS与对照受试者的TTS之间的临床相关性和统计学显着性差异确定，并且存在统计学显着差异确定候选组合物可用于预防或治疗噪声 - 诱发听力损失。

公开(公告)号：WO2021217043A1

公开(公告)日：2021-10-28

申请号：PCT/US2021/028909

申请日：2021-04-23

Applicant: SOUND PHARMACEUTICALS INC.

Inventor： KIL, Jonathan

IPC: A61K31/095 ,  A61K31/375 ,  A61K38/06

Abstract: Provided herein are methods and compositions related to using ebselen for treating acute lung infections and related conditions or diseases. In certain embodiments the methods relate to treating coronavirus-mediated lung injuries. Also provided are methods of treating a patient who has a confirmed or suspected viral lung infection, comprising administering a therapeutically effective amount of ebselen to a patient suffering from a viral lung infection. Also provided are methods of treating a patient who has or is at risk for cytokine release syndrome (CRS), comprising administering an effective amount of ebselen to a patient who has, or is at risk for, CRS. In another aspect, provided herein is a pharmaceutical comprising ebselen, and an antiviral agent that is useful in the methods of this disclosure.